Con: Nutritional vitaminDreplacement in chronic kidney disease and end-stage renal disease
dc.contributor.author | Agarwal, Rajiv | |
dc.contributor.author | Georgianos, Panagiotis I. | |
dc.contributor.department | Department of Medicine, IU School of Medicine | en_US |
dc.date.accessioned | 2016-12-09T15:54:12Z | |
dc.date.available | 2016-12-09T15:54:12Z | |
dc.date.issued | 2016 | |
dc.description.abstract | Insufficiency of 25-hydroxyvitamin D [25(OH)D] is highly prevalent among patients with chronic kidney disease (CKD) or end-stage renal disease (ESRD) and is a critical component in the pathogenesis of secondary hyperparathyroidism. Accordingly, current National Kidney Foundation—Kidney Disease Outcomes Quality Initiative and Kidney Disease: Improving Global Outcomes guidelines recommend the correction of hypovitaminosis D through nutritional vitamin D replacement as a first-step therapeutic approach targeting secondary hyperparathyroidism. In this Polar Views debate, we summarize the existing evidence, aiming to defend the position that nutritional vitamin D replacement is not evidence-based and should not be applied to patients with CKD. This position is supported by the following: (i) our meta-analysis of randomized controlled trials shows that whereas nutritional vitamin D significantly increases serum 25(OH)D levels relative to placebo, there is no evidence either in predialysis CKD or in ESRD that parathyroid hormone (PTH) is lowered; (ii) on the other hand, in randomized head-to-head comparisons, nutritional vitamin D is shown to be inferior to activated vitamin D analogs in reducing PTH levels; (iii) nutritional vitamin D is reported to exert minimal to no beneficial actions in a series of surrogate risk factors, including aortic stiffness, left ventricular mass index (LVMI), epoetin utilization and immune function among others; and (iv) there is no evidence to support a benefit of nutritional vitamin D on survival and other ‘hard’ clinical outcomes. Whereas nutritional vitamin D replacement may restore 25(OH)D concentration to near normal, the real target of treating vitamin D insufficiency is to treat secondary hyperparathyroidism, which is untouched by nutritional vitamin D. Furthermore, the pleotropic benefits of nutritional vitamin D remain to be proven. Thus, there is little, if any, benefit of nutritional vitamin D replacement in CKD. | en_US |
dc.eprint.version | Final published version | en_US |
dc.identifier.citation | Agarwal, R., & Georgianos, P. I. (2016). Con: Nutritional vitamin D replacement in chronic kidney disease and end-stage renal disease. Nephrology Dialysis Transplantation, 31(5), 706-713. | en_US |
dc.identifier.uri | https://hdl.handle.net/1805/11591 | |
dc.language.iso | en | en_US |
dc.publisher | Oxford | en_US |
dc.relation.isversionof | 10.1093/ndt/gfw080 | en_US |
dc.relation.journal | Nephrology Dialysis Transplantation | en_US |
dc.rights | CC0 1.0 Universal | |
dc.rights.uri | http://creativecommons.org/publicdomain/zero/1.0/ | |
dc.source | Publisher | en_US |
dc.subject | cholecalciferol | en_US |
dc.subject | CKD | en_US |
dc.subject | nutritional vitamin D | en_US |
dc.title | Con: Nutritional vitaminDreplacement in chronic kidney disease and end-stage renal disease | en_US |
dc.type | Article | en_US |